Advanced glycation end products (AGEs) may play a role in the pathogenesis of diabetic nephropathy, by modulating extracellular matrix turnover. AGEs are known to activate specific membrane receptors, including the receptor for AGE (RAGE). In the present study, we analyzed the various receptors for AGEs expressed by human mesangial cells and we studied the effects of glycated albumin and of carboxymethyl lysine on matrix protein and remodelling enzyme synthesis. Membrane RAGE expression was confirmed by FACS analysis. Microarray methods, RT-PCR, and Northern blot analysis were used to detect and confirm specific gene induction. Zymographic analysis and ELISA were used to measure the induction of tPA and PAI-1. We show herein that cultured h...
Tubulointerstitial disease, a prominent phenomenon in diabetic nephropathy, correlates with decline ...
Nonenzymatic glycation has been implicated in the pathogenesis of the dysregulated tissue remodeling...
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in...
Introduction Advanced glycation end-products (AGEs) are implicated in the pathogenesis of diabetic n...
Diabetic nephropathy (DN) is a major cause of morbidity and mortality in diabetic patients and a lea...
AGEs activate mesangial TGF-β–Smad signaling via an angiotensin II type I receptor interaction.Backg...
BACKGROUND: Advanced glycation end-products (AGEs) and their receptors are prominent contributors to...
Advanced glycation end products (AGEs) can activate the inflammatory pathways involved in diabetic n...
About 246 million people worldwide had diabetes in 2007. The global figure of people with diabetes i...
Abstract. As is diabetes itself, diabetic vasculopathy is a multi-factor disease. Studies conducted ...
Advanced glycation end products (AGEs) have been thought to be a major cause of diabetic nephropathy...
Role of oxidative stress in advanced glycation end product-induced mesangial cell activation.Backgro...
Advanced glycation end products (AGEs) are compounds classified as uremic toxins in patients with ch...
Advanced glycation endproducts (AGEs) have been confirmed to play a causative role in the developmen...
AbstractAdvanced glycation endproducts (AGEs) are suggested to play an important role in diabetic ne...
Tubulointerstitial disease, a prominent phenomenon in diabetic nephropathy, correlates with decline ...
Nonenzymatic glycation has been implicated in the pathogenesis of the dysregulated tissue remodeling...
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in...
Introduction Advanced glycation end-products (AGEs) are implicated in the pathogenesis of diabetic n...
Diabetic nephropathy (DN) is a major cause of morbidity and mortality in diabetic patients and a lea...
AGEs activate mesangial TGF-β–Smad signaling via an angiotensin II type I receptor interaction.Backg...
BACKGROUND: Advanced glycation end-products (AGEs) and their receptors are prominent contributors to...
Advanced glycation end products (AGEs) can activate the inflammatory pathways involved in diabetic n...
About 246 million people worldwide had diabetes in 2007. The global figure of people with diabetes i...
Abstract. As is diabetes itself, diabetic vasculopathy is a multi-factor disease. Studies conducted ...
Advanced glycation end products (AGEs) have been thought to be a major cause of diabetic nephropathy...
Role of oxidative stress in advanced glycation end product-induced mesangial cell activation.Backgro...
Advanced glycation end products (AGEs) are compounds classified as uremic toxins in patients with ch...
Advanced glycation endproducts (AGEs) have been confirmed to play a causative role in the developmen...
AbstractAdvanced glycation endproducts (AGEs) are suggested to play an important role in diabetic ne...
Tubulointerstitial disease, a prominent phenomenon in diabetic nephropathy, correlates with decline ...
Nonenzymatic glycation has been implicated in the pathogenesis of the dysregulated tissue remodeling...
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in...